PRQR
OtherProQR Therapeutics N.V
$1.72+0.09 (+5.52%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PRQR Today?
No stock-specific AI insight has been generated for PRQR yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$181M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume492K
Avg Volume (10D)—
Shares Outstanding105.4M
PRQR News
20 articles- Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to DeclineYahoo Finance·May 7, 2026
- 3 Promising Penny Stocks With Market Caps Up To $600MYahoo Finance·May 6, 2026
- ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026Yahoo Finance·May 4, 2026
- Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·Apr 30, 2026
- ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsYahoo Finance·Apr 30, 2026
- ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventGlobeNewswire Inc.·Apr 8, 2026
- ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This QuarterMarketbeat·Apr 8, 2026
- ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory BoardYahoo Finance·Apr 8, 2026
- April 2026 Penny Stock HighlightsYahoo Finance·Apr 3, 2026
- Oppenheimer Predicts Up to ~560% Rally for These 2 ‘Strong Buy’ StocksYahoo Finance·Mar 29, 2026
- Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical CatalystsYahoo Finance·Mar 25, 2026
- ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026Yahoo Finance·Mar 25, 2026
- ProQR (PRQR) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 12, 2026
- ProQR: Q4 Earnings SnapshotYahoo Finance·Mar 12, 2026
- ProQR Announces Year End 2025 Operating and Financial ResultsYahoo Finance·Mar 12, 2026
- Kamada (KMDA) Q4 Earnings and Revenues Miss EstimatesYahoo Finance·Mar 11, 2026
- Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 10, 2026
- ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences ConferenceYahoo Finance·Mar 3, 2026
- Puma Biotech (PBYI) Q4 Earnings and Revenues Beat EstimatesYahoo Finance·Feb 26, 2026
- ProQR Announces Planned Changes to Board CompositionYahoo Finance·Feb 9, 2026
All 20 articles loaded
Price Data
Open$1.63
Previous Close$1.63
Day High$1.70
Day Low$1.59
52 Week High—
52 Week Low—
Fundamentals
Market Cap$181M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume492K
Avg Volume (10D)—
Shares Outstanding105.4M
About ProQR Therapeutics N.V
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SIC—
CIK—
Composite FIGI—
Share Class FIGI—